Driven by excellence, focused on strategies for the longer term.

This is the crux of who we are. It is an articulation of precision in purpose, from the Firm’s beginnings to where we are today. Our collective eye is unerringly trained on tomorrow.

Deep sectoral expertise across services and industries.

Our insistence on strategic advisory exacts an in-depth understanding of and involvement with our clients’ businesses and industries. We engage not just individual businesses, but also contribute to the country’s legal and regulatory frameworks.

Personal commitment supported by experience and grit.

We commit early. We pull together internally for greater support. Every effort is sincere, every individual deeply dedicated to their task, their role, to the Firm.

Our undertakings for long-term impact are an organic extension of our purpose.

They are to employ our deep knowledge of the law beyond the business, the transaction, the deal. To use the opportunities and skills we possess, to reflect on the culture we’re creating. Individually and collectively, these are our efforts to help shape the thinking of our future generations, and arm them with strategies for true, sustainable growth.

Knowledge-sharing is intrinsic to equity and inclusivity.

This is a repository of thought leadership, deep insights and strong viewpoints, legal and other news and events and how they impact the industry and our clients.

Relevance is critical to growth. It necessitates a firm that is dynamic and responsive.

Amplifying intrinsic talent, sharpening skills, expanding knowledge, is vital to leading. It defines every aspect of how our firm functions and transacts. This is how we create new benchmarks and set industry standards.

left arrow Oct 09, 2026

UBS Securities India Private Limited and BNP Paribas Securities India Private Limited in relation to sale of 9,897,000 equity shares of Gland Pharma Limited by Fosun Pharma Industrial Pte. Ltd.

AZB & Partners advised UBS Securities India Private Limited and BNP Paribas Securities India Private Limited in relation to sale of 9,897,000 equity shares of Gland Pharma Limited by Fosun Pharma Industrial Pte. Ltd. for an amount aggregating to INR 28 billion. The sale took place on the floor of the stock exchanges via screen-based trading platform.

The deal team comprised our Senior Partner Varoon Chandra; our Partner Rahul Aggarwal; and our Senior Associate Tanaiy Tewari.

AUTHORS & CONTRIBUTORS

TAGS

SHARE

Subscribe

DISCLAIMER

These are the views and opinions of the author(s) and do not necessarily reflect the views of the Firm. This article is intended for general information only and does not constitute legal or other advice and you acknowledge that there is no relationship (implied, legal or fiduciary) between you and the author/AZB. AZB does not claim that the article's content or information is accurate, correct or complete, and disclaims all liability for any loss or damage caused through error or omission.

RELATED READING

Deals

UBS Securities India Private Limited and BNP Paribas Securities India Private Limited in relation to sale of 9,897,000 equity shares of Gland Pharma Limited by Fosun Pharma Industrial Pte. Ltd.
Oct 09, 2026 | Capital Markets
Deals

3one4 Capital on its investments in the US and Indian entities of Cradlewise Inc. as part of its Series A capital raise.
Oct 09, 2026 | Private Equity & Venture Capital
Deals

HSBC Securities and Capital Markets (India) Private Limited on the sale of units of Cube Highways Trust by an affiliate of Mubadala aggregating to approximately INR 6.8 billion on the floor of the exchanges.
Oct 09, 2026 | Capital Markets